Gerald Calegan, MD
Neurology · Baton Rouge, LANPI 1902873516
Payments from drug & device makers
Across 2,531 payments — averaging $158.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$226K
- Teva Pharmaceuticals USA, Inc.$79K
- AbbVie$26K
- Neurocrine Biosciences, Inc.$19K
- Abbott$12K
- Medtronic$12K
- plus $27K from 51 others
What the payments were for
- Consulting fees$23,4736%
- Speaking & faculty fees$299,73475%
- Travel & lodging$24,8846%
- Food & beverage$51,26813%
- Education$5370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$219,602
- Austedo XR$42,927
- AUSTEDO$33,057
- UBRELVY$18,411
- INGREZZA$15,798
- INFINITY$8,387
- RYTARY$6,400
- ACTIVA$6,118
- QULIPTA$2,400
- GOCOVRI$1,213
- SenSight$242
- Percept$213
- LIORESAL$193
- VYVGART HYTRULO$180
- KISUNLA$124
- DAXXIFY$123
- Leqembi$122
- CREXONT$112
- LONHALA MAGNAIR$108
- PERCEPT PC BRAINSENSE$106
How this compares
$399,897 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 459 | $2,248,196 |
| RytaryCarbidopa/Levodopa | 410 | $449,908 |
| AustedoDeutetrabenazine | 35 | $426,677 |
| Austedo XrDeutetrabenazine | 32 | $366,168 |
| IngrezzaValbenazine Tosylate | 38 | $311,550 |
| XeominIncobotulinumtoxina | 65 | $74,523 |
| BotoxOnabotulinumtoxina | 44 | $63,363 |
| GocovriAmantadine Hcl | 15 | $51,468 |
| Rasagiline Mesylate | 291 | $46,504 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,088 | $43,130 |
| UbrelvyUbrogepant | 32 | $39,663 |
| DysportAbobotulinumtoxina | 28 | $24,318 |
| Entacapone | 134 | $16,183 |
| Nurtec OdtRimegepant Sulfate | 15 | $15,996 |
| XadagoSafinamide Mesylate | 13 | $14,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $226,074 | $2,248,196459 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $78,585 | $792,84467 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $7,578 | $450,909427 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $18,778 | $311,55038 claims |
| AbbVieBotox, Ubrelvy | $25,914 | $103,02576 claims |
| MDD US Operations, LLCGocovri | $1,009 | $51,46815 claims |
| Ipsen Biopharmaceuticals, IncDysport | $534 | $24,31828 claims |
| PfizerNurtec Odt | $969 | $15,99615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.
Other neurology in Baton Rouge
- Jon OlsonBaton Rouge$1.7M
- Kevin CallerameBaton Rouge$420K
- Benjamin KidderBaton Rouge$35K
- Joseph AcostaBaton Rouge$33K
- William GladneyBaton Rouge$19K
- David GlossBaton Rouge$15K
- Ariel Antezana AntezanaAlexandria$2.5M
- Bridget BagertNew Orleans$1.4M
- Carol RedillasChalmette$1.3M
- Joseph TarsiaNew Orleans$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.